NCT06641284View on ClinicalTrials.gov

Gender-Based Differences in Heart Failure Hospitalizations Among Patients With Heart Failure Treated With Spironolactone

CompletedOBSERVATIONAL
Enrollment

509

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

October 15, 2024

Study Completion Date

October 15, 2024

Conditions
Heart FailureHeart Failure With Reduced Ejection FractionHeart Failure NYHA Class IIHeart Failure NYHA Class IIIHeart Failure NYHA Class IV
Interventions
DRUG

Spironolactone

All patients will receive Spironolactone as a part of their GDMT for Heart Failure

Trial Locations (1)

Unknown

King Fahd Central Hospital, Al ‘Usaylah

All Listed Sponsors
lead

Ahmad Abdullah Salawi

OTHER_GOV

NCT06641284 - Gender-Based Differences in Heart Failure Hospitalizations Among Patients With Heart Failure Treated With Spironolactone | Biotech Hunter | Biotech Hunter